Personalized Skin Cancer Vaccine Shows Promise in Halving Death Risk
A novel mRNA-based vaccine, Intisomeran, has demonstrated significant success in a phase three trial, reducing the risk of death or recurrence of melanoma by 42% when used alongside immunotherapy.
A groundbreaking personalized vaccine for melanoma, the deadliest form of skin cancer, has shown a significant reduction in the risk of death or cancer recurrence, according to a phase three clinical trial. The vaccine, known as Intisomeran, utilizes mRNA technology similar to that used in COVID-19 vaccines and has demonstrated a 42% decrease in the likelihood of melanoma spreading or returning over a two-year period when administered alongside the immunotherapy drug pembrolizumab.
Melanoma affects approximately 21,000 people annually in the UK, with survival rates dropping sharply once the cancer has metastasized to lymph nodes or distant organs. The trial, which involved 1,137 patients whose surgically removed tumors were at high risk of recurrence, saw two-thirds receive the personalized vaccine while the remainder received a placebo. All participants were treated with pembrolizumab for one year.
Intisomeran is tailored to each patient by analyzing their individual tumors. This process helps to train the patient's immune system to better identify and target cancer cells. The study, slated for presentation at the European Society of Medical Oncology (ESMO) conference in Madrid, found that for every 100 patients treated, an additional 12 remained cancer-free two years post-treatment compared to those receiving immunotherapy alone. However, about six more patients experienced treatment-related side effects, such as fever, fatigue, and injection site reactions.
Experts have hailed the results as a potential turning point in cancer treatment. "Melanoma is leading the way, but vaccines are being investigated in many other cancers, including cancers that are very difficult to treat and don’t respond well to current immune-based treatments," said Professor Alan Melcher of the Institute of Cancer Research London. He added that the medical community is closer than ever to integrating cancer vaccines into routine care.
Drug manufacturers MSD and Moderna are reportedly testing this approach against other cancers, including kidney, bladder, and lung cancer, with plans to seek regulatory approval as early as next year. The widespread adoption by healthcare systems like the NHS may depend on cost, given the individualized nature of vaccine production. Further monitoring of trial participants is ongoing to assess long-term survival benefits and the potential for cancer recurrence.